Use of synthetic peptides for the detection and quantification of autoantibodies
- 1 June 1992
- journal article
- review article
- Published by Springer Nature in Molecular Biology Reports
- Vol. 16 (3) , 207-212
- https://doi.org/10.1007/bf00464709
Abstract
The rapid progress made over the last 10 years in the identification of individual autoantigens and in the localization of the epitopes involved, has resulted in a parallel reduction in the complexity of the antigen required for the detection of autoantibodies. The ability to use synthetic peptides as antigens is a remarkable culmination of this process considering that many antigenic particles contain multiple proteins (eg. Sm consist of 8 or more individual proteins). Despite the fact that patients with SLE have a polyclonal hypergammaglobulinemia, excellent correlations between ELISAs utilizing the P2 or SmB/B′ synthetic peptides, ELISAs utilizing r proteins and immunoblotting were obtained [28, 38, 50]. However, false positive/non-specific binding to a P2-BSA-glutaraldehyde conjugate has been observed with serum from old MRL/lpr mice (unpublished observations). In addition, some of the results obtained in human autoimmune diseases suggest that non-specific binding may be problematic in some instances. It is difficult, at present, to know whether the higher frequencies of detection of autoantibodies to certain synthetic peptide antigens reflect increased sensitivity or decreased specificity. Synthetic peptide antigens have beeen used to detect autoantibodies in both organ specific and multisystem autoimmune diseases. In only a small number of cases have these reagents been rigorously tested for sensitivity and specificity. Despite this, synthetic peptides have been shown to be valuable for detection and quantification of autoantibodies in certain clinical situations. Undoubtedly, further progress in epitope mapping of autoantigens coupled with technological advances in protein synthesis and improved prediction of protein structure will lead to a large number of synthetic peptide antigens for research and clinical applications. It is unlikely that short synthetic peptides will substitute for native proteins in all instances since some autoantibodies show a striking preference for conformational epitopes.Keywords
This publication has 52 references indexed in Scilit:
- A synthetic oligopeptide derived from human thyrotropin receptor sequence binds to Graves' immunoglobulin and inhibits thyroid stimulating antibody activity but lacks interactions with TSHBiochemical and Biophysical Research Communications, 1991
- Detection and quantification of human anti‐Sm antibodies using synthetic peptide and recombinant SmB antigensArthritis & Rheumatism, 1991
- An Insertion in the Human Thyrotropin Receptor Critical for High Affinity Hormone BindingScience, 1990
- Recognition of synthetic peptides of Sm-D autoantigen by lupus seraClinical and Experimental Immunology, 1990
- Identification of immunogenic regions in human thyrotropin receptor for immunoglobulin G of patients with Graves' diseaseBiochemical and Biophysical Research Communications, 1990
- CHEMICAL SYNTHESIS OF PEPTIDES AND PROTEINSAnnual Review of Biochemistry, 1988
- The autoepitope of the 74-kD mitochondrial autoantigen of primary biliary cirrhosis corresponds to the functional site of dihydrolipoamide acetyltransferase.The Journal of Experimental Medicine, 1988
- Antinuclear antibodies (ANAs): Diagnostically specific immune markers and clues toward the understanding of systemic autoimmunityClinical Immunology and Immunopathology, 1988
- Association between Lupus Psychosis and Antiribosomal P Protein AntibodiesNew England Journal of Medicine, 1987
- Patterns of antihistone antibody specificity in systemic rheumatic disease. I. Systemic lupus erythematosus, mixed connective tissue disease, primary sicca syndrome, and rheumatoid arthritis with vasculitisArthritis & Rheumatism, 1985